Besides, CINhigh tumors with chronic STING activation have shown decreased levels of STING in cancer cells.[34] Consequently, administering STING agonists may not be ideal for tumors with a CINhigh phenotype, further promoting tumor growth. This evidence concerns the gene STING1 and neoplasm.